Liquid biopsies and patient-reported outcome measures for integrative monitoring of patients with early-stage breast cancer: a study protocol for the longitudinal observational Prospective Breast Cancer Biobanking (PBCB) study

Abstract

IntroductionBreast cancer is still the most common malignancy among women worldwide. The Prospective Breast Cancer Biobank (PBCB) collects blood and urine from patients with breast cancer every 6 or 12 months for 11 years from 2011 to 2030 at two university hospitals in Western Norway. The project aims to identify new biomarkers that enable detection of systemic recurrences at the molecular level. As blood represents the biological interface between the primary tumour, the microenvironment and distant metastases, liquid biopsies represent the ideal medium to monitor the patient‘s cancer biology for identification of patients at high risk of relapse and for early detection systemic relapse.Including patient-reported outcome measures (PROMs) allows for a vast number of possibilities to compare PROM data with biological information, enabling the study of fatigue and Quality of Life in patients with breast cancer.Methods and analysisA total of 1455 patients with early-stage breast cancer are enrolled in the PBCB study, which has a one-armed prospective observational design. Participants consent to contribute liquid biopsies (i.e., peripheral blood and urine samples) every 6 or 12 months for 11 years. The liquid biopsies are the basis for detection of circulating tumour cells, circulating tumour DNA (ctDNA), exosomal micro-RNA (miRNA), miRNA in Tumour Educated Platelet and metabolomic profiles. In addition, participants respond to 10 PROM questionnaires collected annually. Moreover, a control group comprising 200 women without cancer aged 25–70 years will provide the same data.Ethics and disseminationThe general research biobank PBCB was approved by the Ministry of Health and Care Services in 2007, by the Regional Ethics Committee (REK) in 2010 (#2010/1957). The PROM (#2011/2161) and the biomarker study PerMoBreCan (#2015/2010) were approved by REK in 2011 and 2015 respectively. Results will be published in international peer reviewed journals. Deidentified data will be accessible on request.Trial registration numberNCT04488614.

Assessing Mode of Recurrence in Breast Cancer to Identify an Optimised Follow-Up Pathway: 10-Year Institutional Review

“…In these patients, the role of other modalities such as circulating tumour DNA or miRNA obtained by liquid biopsy, which have shown significant promise and are the subject of ongoing prospective studies, may also become more prominent within surveillance programmes for breast cancer, especially in younger patients with triple-negative disease. 37 – 40 …”

The Organization of Contemporary Biobanks for Translational Cancer Research

“…Biosamples collected to study cancer include malignant as well as normal neighboring tissue and liquid biopsies in the form of peripheral blood, plasma, serum, pleural effusions, peritoneal effusions, urine, and saliva. Peripheral blood mononuclear cells (PBMCs) and genetic material consisting of DNA/RNA (extracted from normal and tumor cells), plasma-derived cell-free DNA and cell-free tumor DNA, micro-RNAS (miRNAs), as well as clinicopathologic data can also be collected in biobanks [4][5][6]. Such cancer-related samples, along with their accompanying clinicopathological parameters and demographics, are integrated in databases for future analyses, which makes it important to have as much as possible detailed and current relevant information at every time point of biosampling.…”

Passive Microwave Radiometry and microRNA Detection for Breast Cancer Diagnostics

“…MicroRNAs (miRNAs) are small, non-coding RNA molecules. With their tissuespecific expression, correlation with clinicopathological prognostic indices, and known dysregulation in breast cancer, miRNAs have quickly become an important avenue in the search for novel breast cancer biomarkers [3][4][5].…”